Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) saw unusually-high trading volume on Friday . Approximately 844,520 shares were traded during trading, an increase of 13% from the previous session's volume of 748,544 shares.The stock last traded at $44.50 and had previously closed at $45.71.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 3rd. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price for the company. Guggenheim restated a "buy" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. UBS Group reduced their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, B. Riley upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $38.00 to $60.00 in a research note on Tuesday, June 3rd. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $59.78.

Kymera Therapeutics Trading Down 2.3%

The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -14.41 and a beta of 2.07. The company has a fifty day simple moving average of $36.72 and a 200-day simple moving average of $35.87.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The company's revenue was up 114.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.69) EPS. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the completion of the sale, the chief executive officer now directly owns 660,482 shares of the company's stock, valued at approximately $32,363,618. The trade was a 4.34% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,349 shares of company stock valued at $2,334,301. Corporate insiders own 16.01% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in shares of Kymera Therapeutics by 13.0% in the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after buying an additional 689,547 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after acquiring an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in Kymera Therapeutics during the 4th quarter valued at $23,856,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after purchasing an additional 491,737 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Kymera Therapeutics in the 4th quarter worth $17,098,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.